echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Pfizer launches zavicefta, a new antibiotic product in Europe Gamma

    Pfizer launches zavicefta, a new antibiotic product in Europe Gamma

    • Last Update: 2017-03-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Sina pharmaceutical 2017-03-16 U.S pharmaceutical giant Pfizer recently announced the launch of zavicefta (ceftazidime avibactam, caz-avi, ceftazidime avibatan, 2G / 0.5g, powder) in the first batch of European countries - the United Kingdom and Germany, which is used for the treatment of severe gram-negative bacterial infections requiring hospitalization Pfizer said it will continue to push zavicefta to other markets outside the United States between 2017 and 2018 At present, multidrug resistance (MDR) infection has become an increasingly serious global threat The market of zavicefta will solve the urgent medical needs of new antibiotics in this field Zavicefta is jointly developed by AstraZeneca, a British pharmaceutical giant, and Allergan, an Irish pharmaceutical company Allergan has the right to the product in the North American market, while AstraZeneca has the right to commercialize the product in other parts of the world In August 2016, Pfizer and AstraZeneca entered into an agreement to purchase AstraZeneca's small molecule antibiotic business, including zavicefta, for us $1.6 billion In Europe, zavicefta was approved by the European Drug Administration (EMA) in June 2016 The specific indications are: using zavicefta for intravenous infusion, treating complex intra-abdominal infection (Ciai), complex urinary tract infection (ctui, including pyelonephritis), hospital acquired pneumonia (HAP, including ventilator-associated pneumonia) VAP) adult patients, as well as those infected by aerobic gram-negative bacteria but with limited treatment options In the United States, caz-avi was approved by FDA in February 2015, with the brand name of avycaz Zavicefta (ceftazidime avibactam, caz-avi, ceftazidime avibactam) is composed of a broad-spectrum cephalosporin ceftazidime and a new generation of non β - lactam β - lactamase inhibitors The compound product composed of avibactam (Avi Batan) is developed for the treatment of a wide range of gram-negative bacterial infections, including multiple drug resistant Pseudomonas aeruginosa, carbapenem resistant gram-negative bacteria, producing extended spectrum β - lactamases (ESBLs) Enterobacteriaceae Ceftazidime (ceftazidime) is the third generation cephalosporin, which is an antibiotic product commonly used to treat severe gram-negative bacterial infection The avibactam component added in zavicefta will protect ceftazidime from being decomposed by β - lactamase produced by these resistant negative bacteria At the end of last month, the World Health Organization (who) released a list of 12 serious pathogens (click to see: who priority pathogens list for R & D of new antibiotics), in which Gram-negative bacteria (G-bacteria) are particularly prominent, and the three pathogens listed in the key item (critical) are all Gram-negative bacteria, including: Acinetobacter baumannii (Acinetobacter baumannii) Baumannii, carbapenem resistant, Pseudomonas aeruginosa, Enterobacteriaceae (ESBL) It is gratifying that Zavicefta will address the urgent medical needs for infection with 2 of these Gram-negative bacteria (Pseudomonas aeruginosa, Enterobacteriaceae) At present, the increasingly serious problem of antibiotic resistance has posed a serious threat to public health In Europe, the number of deaths caused by antibiotic resistance is as high as 25000 every year, of which two-thirds are caused by gram-negative bacteria In the face of severe gram-negative bacterial infection, many effective treatment programs will soon lose efficacy Zavicefta, as an important supplement to the global ammunition bank against multidrug resistant bacteria, will help to fill this gap and enable more patients to benefit from this new antibiotic product.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.